Clinical Trial

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)

Study acronym: BLESS
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-23.
Status change: Not Yet Recruiting → Recruiting 2024-06-28
Trial Details
NCT Number NCT06385730
Lead Sponsor Shanghai Chest Hospital
Conditions Esophageal Cancer
Enrollment 60 participants
Start Date 2024-06-17
Primary Completion 2025-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2024-07-01